Dr. Schayowitz has served as our Acting Chief Development Officer since October 2025. Dr. Schayowitz brings nearly 20 years of experience in oncology drug development to Zymeworks, having led dozens of global development programs from initiation through approval and commercialization. Prior to joining EcoR1 as an Operating Partner, he was a Vice President at Pfizer Oncology holding various development leadership roles across breast cancer, prostate cancer, colorectal cancer and melanoma, ultimately culminating in serving as Head of Product Development Teams. Prior to Pfizer, Dr. Schayowitz led the development of Zejula (niraparib) at Tesaro and was a member of the Medical Affairs leadership team at Algeta supporting the commercialization of Xofigo (Radium-223). He is currently a Board Member at Terremoto Biosciences and serves as a Board Observer for Aktis Oncology. Dr. Schayowitz has a BA from Hamilton College, a Ph.D. in Pharmacology from The University of Maryland, and an MBA from Johns Hopkins.